Cabotegravir Sodium (BioDeep_00000839651)
代谢物信息卡片
Cabotegravir Sodium
化学式: C19H16F2N3NaO5 (427.095567)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)[O-].[Na+]
InChI: /q
描述信息
D004791 - Enzyme Inhibitors > D019429 - Integrase Inhibitors > D019428 - HIV Integrase Inhibitors
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D054659 - Diketopiperazines
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:172948
- KEGGdrug: D10549
- PubChem: 46215800
- ChEMBL: CHEMBL3137330
- CAS: 1229006-16-9
- CAS: 1051375-13-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Eisuke Adachi, Makoto Saito, Amato Otani, Michiko Koga, Hiroshi Yotsuyanagi. Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine.
AIDS research and therapy.
2024 01; 21(1):1. doi:
10.1186/s12981-023-00590-4. [PMID: 38173008] - Xiu Chen, Jun Li, Liqiu Kou, Xiaolu Xie, Deqing Wei, Yaling Li. Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
Reviews in medical virology.
2023 May; ?(?):e2460. doi:
10.1002/rmv.2460. [PMID: 37198721] - Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, Gordon Chau, Vanessa Cummings, Yaw Agyei, Paul Richardson, Philip Sullivan, Casey D Haines, Lane R Bushman, Christos Petropoulos, Deborah Persaud, Ryan Kofron, Craig W Hendrix, Peter L Anderson, Jennifer Farrior, John Mellors, Adeola Adeyeye, Alex Rinehart, Marty St Clair, Susan Ford, James F Rooney, Carrie-Anne Mathew, Portia Hunidzarira, Elizabeth Spooner, Juliet Mpendo, Gonasagrie Nair, Myron S Cohen, James P Hughes, Mina Hosseinipour, Brett Hanscom, Sinead Delany-Moretlwe, Mark A Marzinke. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
The Journal of infectious diseases.
2022 05; 225(10):1741-1749. doi:
10.1093/infdis/jiab576. [PMID: 35301540] - Inken K Ramöller, Marco T A Abbate, Lalitkumar K Vora, Aaron R J Hutton, Ke Peng, Fabiana Volpe-Zanutto, Ismaiel A Tekko, Kurtis Moffatt, Alejandro J Paredes, Helen O McCarthy, Ryan F Donnelly. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues.
Journal of pharmaceutical and biomedical analysis.
2022 May; 213(?):114698. doi:
10.1016/j.jpba.2022.114698. [PMID: 35259714] - Sinead Delany-Moretlwe, James P Hughes, Peter Bock, Samuel Gurrion Ouma, Portia Hunidzarira, Dishiki Kalonji, Noel Kayange, Joseph Makhema, Patricia Mandima, Carrie Mathew, Elizabeth Spooner, Juliet Mpendo, Pamela Mukwekwerere, Nyaradzo Mgodi, Patricia Nahirya Ntege, Gonasagrie Nair, Clemensia Nakabiito, Harriet Nuwagaba-Biribonwoha, Ravindre Panchia, Nishanta Singh, Bekezela Siziba, Jennifer Farrior, Scott Rose, Peter L Anderson, Susan H Eshleman, Mark A Marzinke, Craig W Hendrix, Stephanie Beigel-Orme, Sybil Hosek, Elizabeth Tolley, Nirupama Sista, Adeola Adeyeye, James F Rooney, Alex Rinehart, William R Spreen, Kimberly Smith, Brett Hanscom, Myron S Cohen, Mina C Hosseinipour. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Lancet (London, England).
2022 05; 399(10337):1779-1789. doi:
10.1016/s0140-6736(22)00538-4. [PMID: 35378077] - Vasiliki Chounta, Sonya J Snedecor, Sterling Wu, Nicolas Van de Velde. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
BMC infectious diseases.
2022 May; 22(1):428. doi:
10.1186/s12879-022-07243-3. [PMID: 35508986] - Sangeeta Pandey, Yanyang Hu, Lane R Bushman, Jose Castillo-Mancilla, Peter L Anderson, R Graham Cooks. Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood.
Analytical and bioanalytical chemistry.
2022 May; 414(11):3387-3395. doi:
10.1007/s00216-022-03954-3. [PMID: 35169905] - Kelong Han, Paul Wannamaker, Hongzhou Lu, Biao Zhu, Meixia Wang, Melanie Paff, William R Spreen, Susan L Ford. Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
Antimicrobial agents and chemotherapy.
2022 03; 66(3):e0205721. doi:
10.1128/aac.02057-21. [PMID: 35129374] - Beat M Jucker, Edward J Fuchs, Sarah Lee, Valeriu Damian, Paul Galette, Robert Janiczek, Katarzyna J Macura, Michael A Jacobs, Ethel D Weld, Meiyappan Solaiyappan, Ronald D'Amico, Jafar Sadik Shaik, Kalpana Bakshi, Kelong Han, Susan Ford, David Margolis, William Spreen, Manish K Gupta, Craig W Hendrix, Parul Patel. Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.
British journal of clinical pharmacology.
2022 02; 88(4):1655-1666. doi:
10.1111/bcp.14977. [PMID: 34240449] - Jafar Sadik Shaik, Ethel D Weld, Stacey Edick, Edward Fuchs, Sharon Riddler, Mark A Marzinke, Ronald D'Amico, Kalpana Bakshi, Yu Lou, Craig Hendrix, Kelong Han, Susan L Ford, David Margolis, William Spreen, Parul Patel. Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
British journal of clinical pharmacology.
2022 02; 88(4):1667-1678. doi:
10.1111/bcp.14980. [PMID: 34240467] - Susan Swindells, Thomas Lutz, Lelanie Van Zyl, Norma Porteiro, Matthias Stoll, Essack Mitha, Alyssa Shon, Paul Benn, Jenny O Huang, Conn M Harrington, Kai Hove, Susan L Ford, Christine L Talarico, Vasiliki Chounta, Herta Crauwels, Rodica Van Solingen-Ristea, Simon Vanveggel, David A Margolis, Kimberly Y Smith, Kati Vandermeulen, William R Spreen. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS (London, England).
2022 02; 36(2):185-194. doi:
10.1097/qad.0000000000003025. [PMID: 34261093] - Anthony Mills, Gary J Richmond, Cheryl Newman, Olayemi Osiyemi, Jerry Cade, Cynthia Brinson, Jerome De Vente, David A Margolis, Kenneth C Sutton, Viviana Wilches, Sarah Hatch, Jeremy Roberts, Cynthia McCoig, Cindy Garris, Kati Vandermeulen, William R Spreen. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
AIDS (London, England).
2022 02; 36(2):195-203. doi:
10.1097/qad.0000000000003085. [PMID: 34652287] - Behnaz Eshaghi, Josiane Fofana, Sarah B Nodder, Suryaram Gummuluru, Björn M Reinhard. Virus-Mimicking Polymer Nanoparticles Targeting CD169+ Macrophages as Long-Acting Nanocarriers for Combination Antiretrovirals.
ACS applied materials & interfaces.
2022 Jan; 14(2):2488-2500. doi:
10.1021/acsami.1c17415. [PMID: 34995059] - Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Firaya Nagimova, Fritz Bredeek, Miguel García Deltoro, Susan Swindells, Jaime Federico Andrade-Villanueva, Alexander Wong, Marie-Aude Khuong-Josses, Rodica Van Solingen-Ristea, Veerle van Eygen, Herta Crauwels, Susan Ford, Christine Talarico, Paul Benn, Yuanyuan Wang, Krischan J Hudson, Vasiliki Chounta, Amy Cutrell, Parul Patel, Mark Shaefer, David A Margolis, Kimberly Y Smith, Simon Vanveggel, William Spreen. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet (London, England).
2021 12; 396(10267):1994-2005. doi:
10.1016/s0140-6736(20)32666-0. [PMID: 33308425] - Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, Estelle Piwowar-Manning, Maoji Li, Lei Weng, Marybeth McCauley, Vanessa Cummings, Shahnaz Ahmed, Casey D Haines, Lane R Bushman, Christos Petropoulos, Deborah Persaud, Adeola Adeyeye, Ryan Kofron, Alex Rinehart, Marty St Clair, James F Rooney, Daniel Pryluka, Lara Coelho, Aditya Gaur, Keren Middelkoop, Nittaya Phanuphak, Myron S Cohen, Craig W Hendrix, Peter Anderson, Brett Hanscom, Deborah Donnell, Raphael J Landovitz, Susan H Eshleman. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
The Journal of infectious diseases.
2021 11; 224(9):1581-1592. doi:
10.1093/infdis/jiab152. [PMID: 33740057] - Hans Jaeger, Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Jaime Federico Andrade-Villanueva, Rosie Mngqibisa, Antonio Ocampo Hermida, Anders Thalme, Elena Belonosova, Faïza Ajana, Paul D Benn, Yuanyuan Wang, Krischan J Hudson, Carlos Martín Español, Susan L Ford, Herta Crauwels, David A Margolis, Christine L Talarico, Kimberly Y Smith, Veerle van Eygen, Rodica Van Solingen-Ristea, Simon Vanveggel, William R Spreen. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
The lancet. HIV.
2021 11; 8(11):e679-e689. doi:
10.1016/s2352-3018(21)00185-5. [PMID: 34648734] - Chloe Orkin, Enrique Bernal Morell, Darrell H S Tan, Harold Katner, Hans-Jürgen Stellbrink, Elena Belonosova, Rebecca DeMoor, Sandy Griffith, Shanker Thiagarajah, Rodica Van Solingen-Ristea, Susan L Ford, Herta Crauwels, Parul Patel, Amy Cutrell, Kimberly Y Smith, Kati Vandermeulen, Eileen Birmingham, Marty St Clair, William R Spreen, Ronald D'Amico. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
The lancet. HIV.
2021 11; 8(11):e668-e678. doi:
10.1016/s2352-3018(21)00184-3. [PMID: 34656207] - Nagsen Gautam, JoEllyn M McMillan, Devendra Kumar, Aditya N Bade, Qiaoyu Pan, Tanmay A Kulkarni, Wenkuan Li, Brady Sillman, Nathan A Smith, Bhagya L Dyavar Shetty, Adam Szlachetka, Benson J Edagwa, Howard E Gendelman, Yazen Alnouti. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.
Nature communications.
2021 06; 12(1):3453. doi:
10.1038/s41467-021-23668-x. [PMID: 34103484] - Chloe Orkin, Shinichi Oka, Patrick Philibert, Cynthia Brinson, Ayesha Bassa, Denis Gusev, Olaf Degen, Juan González García, Enrique Bernal Morell, Darrell H S Tan, Ronald D'Amico, David Dorey, Sandy Griffith, Shanker Thiagarajah, Marty St Clair, Rodica Van Solingen-Ristea, Herta Crauwels, Susan L Ford, Parul Patel, Vasiliki Chounta, Simon Vanveggel, Amy Cutrell, Veerle Van Eygen, Kati Vandermeulen, David A Margolis, Kimberly Y Smith, William R Spreen. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
The lancet. HIV.
2021 04; 8(4):e185-e196. doi:
10.1016/s2352-3018(20)30340-4. [PMID: 33794181] - Susan Buchbinder, Albert Liu. CROI 2021: Epidemiologic Trends in the HIV and SARS-CoV-2 Pandemics and HIV Prevention Research.
Topics in antiviral medicine.
2021 Apr; 29(2):309-327. doi:
NULL. [PMID: 34107201] - Dipu Karunakaran, Solange M Simpson, Jonathan T Su, Ewa Bryndza-Tfaily, Thomas J Hope, Ronald Veazey, Georgina Dobek, Jiang Qiu, David Watrous, Samuel Sung, Jorge E Chacon, Patrick F Kiser. Design and Testing of a Cabotegravir Implant for HIV Prevention.
Journal of controlled release : official journal of the Controlled Release Society.
2021 02; 330(?):658-668. doi:
10.1016/j.jconrel.2020.12.024. [PMID: 33347943] - Parul Patel, Zhengyu Xue, Karen S King, Laura Parham, Susan Ford, Yu Lou, Kalpana K Bakshi, Kenneth Sutton, David Margolis, Arlene R Hughes, William R Spreen. Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.
The Journal of antimicrobial chemotherapy.
2020 08; 75(8):2240-2248. doi:
10.1093/jac/dkaa147. [PMID: 32361755] - Tanmay A Kulkarni, Aditya N Bade, Brady Sillman, Bhagya Laxmi Dyavar Shetty, Melinda S Wojtkiewicz, Nagsen Gautam, James R Hilaire, Sruthi Sravanam, Adam Szlachetka, Benjamin G Lamberty, Brenda M Morsey, Howard S Fox, Yazen Alnouti, JoEllyn M McMillan, R Lee Mosley, Jane Meza, Paul L Domanico, Tai-Yuen Yue, Gary Moore, Benson J Edagwa, Howard E Gendelman. A year-long extended release nanoformulated cabotegravir prodrug.
Nature materials.
2020 08; 19(8):910-920. doi:
10.1038/s41563-020-0674-z. [PMID: 32341511] - Perrine Courlet, Susana Alves Saldanha, Matthias Cavassini, Catia Marzolini, Eva Choong, Chantal Csajka, Huldrych F Günthard, Pascal André, Thierry Buclin, Vincent Desfontaine, Laurent Arthur Decosterd. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Journal of mass spectrometry : JMS.
2020 Jun; 55(6):e4506. doi:
10.1002/jms.4506. [PMID: 32160389] - Jon Cohen. Long-acting drug acts like a short-term AIDS vaccine.
Science (New York, N.Y.).
2020 05; 368(6493):807. doi:
10.1126/science.368.6493.807. [PMID: 32439768] - Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, Giuliano Rizzardini, Axel Baumgarten, Mar Masiá, Gulam Latiff, Vadim Pokrovsky, Fritz Bredeek, Graham Smith, Pedro Cahn, Yeon-Sook Kim, Susan L Ford, Christine L Talarico, Parul Patel, Vasiliki Chounta, Herta Crauwels, Wim Parys, Simon Vanveggel, Joseph Mrus, Jenny Huang, Conn M Harrington, Krischan J Hudson, David A Margolis, Kimberly Y Smith, Peter E Williams, William R Spreen. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
The New England journal of medicine.
2020 03; 382(12):1112-1123. doi:
10.1056/nejmoa1904398. [PMID: 32130809] - Scott L Letendre, Anthony Mills, Debbie Hagins, Susan Swindells, Franco Felizarta, Jerome Devente, Christopher Bettacchi, Yu Lou, Susan Ford, Kenneth Sutton, Jafar Sadik Shaik, Herta Crauwels, Ronald D'Amico, Parul Patel. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
The Journal of antimicrobial chemotherapy.
2020 03; 75(3):648-655. doi:
10.1093/jac/dkz504. [PMID: 31873746] - Andrey A Ivashchenko, Yan A Ivanenkov, Angela G Koryakova, Ruben N Karapetian, Oleg D Mitkin, Vladimir A Aladinskiy, Dmitry V Kravchenko, Nikolai P Savchuk, Alexander V Ivashchenko. Synthesis, biological evaluation and in silico modeling of novel integrase strand transfer inhibitors (INSTIs).
European journal of medicinal chemistry.
2020 Mar; 189(?):112064. doi:
10.1016/j.ejmech.2020.112064. [PMID: 31972393] - Mitesh Patel, H Christian Eberl, Andrea Wolf, Esaie Pierre, Joseph W Polli, Maciej J Zamek-Gliszczynski. Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans.
The Journal of pharmacology and experimental therapeutics.
2019 08; 370(2):269-277. doi:
10.1124/jpet.119.258384. [PMID: 31175220] - Fernanda P Pons-Faudoa, Antons Sizovs, Nicola Di Trani, Jesus Paez-Mayorga, Giacomo Bruno, Jessica Rhudy, Madhuri Manohar, Kevin Gwenden, Cecilia Martini, Corrine Ying Xuan Chua, Greta Varchi, Mark A Marzinke, Alessandro Grattoni. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
Journal of controlled release : official journal of the Controlled Release Society.
2019 07; 306(?):89-96. doi:
10.1016/j.jconrel.2019.05.037. [PMID: 31136811] - Ridhi Parasrampuria, Susan L Ford, Yu Lou, Caifeng Fu, Kalpana K Bakshi, Allan R Tenorio, Christine Trezza, William R Spreen, Parul Patel. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants.
Clinical pharmacology in drug development.
2019 07; 8(5):674-681. doi:
10.1002/cpdd.664. [PMID: 30809978] - Jafar Sadik B Shaik, Susan L Ford, Yu Lou, Zhiping Zhang, Kalpana K Bakshi, Allan R Tenorio, Christine Trezza, William R Spreen, Parul Patel. A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls.
Clinical pharmacology in drug development.
2019 07; 8(5):664-673. doi:
10.1002/cpdd.655. [PMID: 30811880] - Parul Patel, Susan L Ford, Yu Lou, Kalpana Bakshi, Allan R Tenorio, Zhiping Zhang, Rennan Pan, William Spreen. Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir.
Clinical pharmacology in drug development.
2019 05; 8(4):443-448. doi:
10.1002/cpdd.620. [PMID: 30230694] - Jessica Radzio-Basu, Olivia Council, Mian-Er Cong, Susan Ruone, Alicia Newton, Xierong Wei, James Mitchell, Shanon Ellis, Christos J Petropoulos, Wei Huang, William Spreen, Walid Heneine, J Gerardo García-Lerma. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
Nature communications.
2019 05; 10(1):2005. doi:
10.1038/s41467-019-10047-w. [PMID: 31043606] - Stephanie N Liu, Jessica Bo Li Lu, Christy J W Watson, Philip Lazarus, Zeruesenay Desta, Brandon T Gufford. Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors.
Drug metabolism and disposition: the biological fate of chemicals.
2019 05; 47(5):535-544. doi:
10.1124/dmd.118.085035. [PMID: 30804050] - JoEllyn McMillan, Adam Szlachetka, Tian Zhou, Brenda Morsey, Benjamin Lamberty, Shannon Callen, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E Gendelman, Howard S Fox. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
AIDS (London, England).
2019 03; 33(3):585-588. doi:
10.1097/qad.0000000000002032. [PMID: 30289818] - Susan L Ford, Yu Lou, Nicole Lewis, Michalis Kostapanos, Ronald D'Amico, William Spreen, Parul Patel. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
Antiviral therapy.
2019; 24(4):301-308. doi:
10.3851/imp3306. [PMID: 30896438] - Raphael J Landovitz, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y Liu, Manya Magnus, Mina C Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Paul Richardson, Mark A Marzinke, Craig W Hendrix, Susan H Eshleman, Yinfeng Zhang, Elizabeth Tolley, Jeremy Sugarman, Ryan Kofron, Adeola Adeyeye, David Burns, Alex R Rinehart, David Margolis, William R Spreen, Myron S Cohen, Marybeth McCauley, Joseph J Eron. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
PLoS medicine.
2018 11; 15(11):e1002690. doi:
10.1371/journal.pmed.1002690. [PMID: 30408115] - Tian Zhou, Hang Su, Prasanta Dash, Zhiyi Lin, Bhagya Laxmi Dyavar Shetty, Ted Kocher, Adam Szlachetka, Benjamin Lamberty, Howard S Fox, Larisa Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, R Lee Mosley, Yazen Alnouti, Benson Edagwa, Howard E Gendelman. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Biomaterials.
2018 Jan; 151(?):53-65. doi:
10.1016/j.biomaterials.2017.10.023. [PMID: 29059541] - Beat M Jucker, Hasan Alsaid, Mary Rambo, Stephen C Lenhard, Bao Hoang, Fang Xie, M Reid Groseclose, Stephen Castellino, Valeriu Damian, Gary Bowers, Manish Gupta. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat.
Journal of controlled release : official journal of the Controlled Release Society.
2017 Dec; 268(?):102-112. doi:
10.1016/j.jconrel.2017.10.017. [PMID: 29042321] - S L Ford, K Sutton, Y Lou, Z Zhang, A Tenorio, C Trezza, P Patel, W Spreen. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
Antimicrobial agents and chemotherapy.
2017 10; 61(10):. doi:
10.1128/aac.00487-17. [PMID: 28739783] - David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Daniel Podzamczer, Thomas Lutz, Jonathan B Angel, Gary J Richmond, Bonaventura Clotet, Felix Gutierrez, Louis Sloan, Marty St Clair, Miranda Murray, Susan L Ford, Joseph Mrus, Parul Patel, Herta Crauwels, Sandy K Griffith, Kenneth C Sutton, David Dorey, Kimberly Y Smith, Peter E Williams, William R Spreen. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet (London, England).
2017 Sep; 390(10101):1499-1510. doi:
10.1016/s0140-6736(17)31917-7. [PMID: 28750935] - Martin Markowitz, Ian Frank, Robert M Grant, Kenneth H Mayer, Richard Elion, Deborah Goldstein, Chester Fisher, Magdalena E Sobieszczyk, Joel E Gallant, Hong Van Tieu, Winkler Weinberg, David A Margolis, Krischan J Hudson, Britt S Stancil, Susan L Ford, Parul Patel, Elizabeth Gould, Alex R Rinehart, Kimberly Y Smith, William R Spreen. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
The lancet. HIV.
2017 08; 4(8):e331-e340. doi:
10.1016/s2352-3018(17)30068-1. [PMID: 28546090] - Christine Trezza, Susan L Ford, Elizabeth Gould, Yu Lou, Chuyun Huang, James M Ritter, Ann M Buchanan, William Spreen, Parul Patel. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.
British journal of clinical pharmacology.
2017 07; 83(7):1499-1505. doi:
10.1111/bcp.13236. [PMID: 28087972] - Chasity D Andrews, Leslie St Bernard, Amanda Yee Poon, Hiroshi Mohri, Natanya Gettie, William R Spreen, Agegnehu Gettie, Kasi Russell-Lodrigue, James Blanchard, Zhi Hong, David D Ho, Martin Markowitz. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
AIDS (London, England).
2017 02; 31(4):461-467. doi:
10.1097/qad.0000000000001343. [PMID: 27902508] - Yu Lou, Ann M Buchanan, Shuguang Chen, Susan L Ford, Elizabeth Gould, David Margolis, William R Spreen, Parul Patel. Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects.
Clinical pharmacology in drug development.
2016 Nov; 5(6):509-516. doi:
10.1002/cpdd.272. [PMID: 27162089] - Melinda J Reese, Gary D Bowers, Joan E Humphreys, Elizabeth P Gould, Susan L Ford, Lindsey O Webster, Joseph W Polli. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
Xenobiotica; the fate of foreign compounds in biological systems.
2016; 46(5):445-56. doi:
10.3109/00498254.2015.1081993. [PMID: 26340566] - Gary David Bowers, Amanda Culp, Melinda J Reese, Glenn Tabolt, Lee Moss, Stephen Piscitelli, Phuong Huynh, David Wagner, Susan L Ford, Elizabeth P Gould, Rennan Pan, Yu Lou, David A Margolis, William R Spreen. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2016; 46(2):147-62. doi:
10.3109/00498254.2015.1060372. [PMID: 26134155] - Christine Trezza, Susan L Ford, William Spreen, Rennan Pan, Stephen Piscitelli. Formulation and pharmacology of long-acting cabotegravir.
Current opinion in HIV and AIDS.
2015 Jul; 10(4):239-45. doi:
10.1097/coh.0000000000000168. [PMID: 26049948] - Jessica Radzio, William Spreen, Yun Lan Yueh, James Mitchell, Leecresia Jenkins, J Gerardo García-Lerma, Walid Heneine. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge.
Science translational medicine.
2015 Jan; 7(270):270ra5. doi:
10.1126/scitranslmed.3010297. [PMID: 25589631] - Tomokazu Yoshinaga, Masanori Kobayashi, Takahiro Seki, Shigeru Miki, Chiaki Wakasa-Morimoto, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki, Teruhiko Taishi, Takashi Kawasuji, Brian A Johns, Mark R Underwood, Edward P Garvey, Akihiko Sato, Tamio Fujiwara. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
Antimicrobial agents and chemotherapy.
2015 Jan; 59(1):397-406. doi:
10.1128/aac.03909-14. [PMID: 25367908] - William Spreen, Peter Williams, David Margolis, Susan L Ford, Herta Crauwels, Yu Lou, Elizabeth Gould, Marita Stevens, Stephen Piscitelli. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults.
Journal of acquired immune deficiency syndromes (1999).
2014 Dec; 67(5):487-92. doi:
10.1097/qai.0000000000000365. [PMID: 25473882] - William Spreen, Susan L Ford, Shuguang Chen, David Wilfret, David Margolis, Elizabeth Gould, Stephen Piscitelli. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects.
Journal of acquired immune deficiency syndromes (1999).
2014 Dec; 67(5):481-6. doi:
10.1097/qai.0000000000000301. [PMID: 25140909] - Chasity D Andrews, William R Spreen, Hiroshi Mohri, Lee Moss, Susan Ford, Agegnehu Gettie, Kasi Russell-Lodrigue, Rudolf P Bohm, Cecilia Cheng-Mayer, Zhi Hong, Martin Markowitz, David D Ho. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.
Science (New York, N.Y.).
2014 Mar; 343(6175):1151-4. doi:
10.1126/science.1248707. [PMID: 24594934] - Susan L Ford, Elizabeth Gould, Shuguang Chen, David Margolis, William Spreen, Herta Crauwels, Stephen Piscitelli. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
Antimicrobial agents and chemotherapy.
2013 Nov; 57(11):5472-7. doi:
10.1128/aac.01235-13. [PMID: 23979733] - W Spreen, S Min, S L Ford, S Chen, Y Lou, M Bomar, M St Clair, S Piscitelli, T Fujiwara. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.
HIV clinical trials.
2013 Sep; 14(5):192-203. doi:
10.1310/hct1405-192. [PMID: 24144896]